Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors (RIMRA)

Diakonhjemmet Hospital

Status: Active, not recruiting

Conditions: Immune-related Adverse Event

Treatments: Other: Antiinflammatory/DMARDs

Study type: Observational

Funder types: Other

Identifiers

NCT05544292

DS 00469

Details and patient eligibility

About

RIMRA is a prospective, longitudinal, observational study including patients with de novo symptoms of rheumatic disease or a flare of established rheumatic disease after treatment with an immune check point inhibitor. The aim of the study is to describe the clinical presentation, disease course and outcome of rheumatic irAEs in patients treated with immune check point inhibitors.

Enrollment: 80 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• De novo symptoms of rheumatic disease or a flare of established rheumatic disease after >/= 1 dose of treatment with an immune check point inhibitor
• Adult patients (> 18 years)
• Subject capable of understanding and signing an informed consent form

Exclusion criteria

• Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol difficult